Janoria Kumar G, Hariharan Sudharshan, Dasari Chanukya R, Mitra Ashim K
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64110-2499, USA.
Recent Pat Drug Deliv Formul. 2007;1(2):161-70. doi: 10.2174/187221107780831923.
Ophthalmic drug delivery has long been a challenging task for pharmaceutical scientists seeking to alleviate various ocular diseases affecting the anterior and posterior segments. In order to deliver therapeutic agents to target tissues, the unique anatomical barriers of the eye must be circumvented effectively, without causing any patient discomfort or alteration in protective physiological mechanisms. This challenge is currently being met with the development of novel non-invasive delivery methods as well as improvements over existing techniques. Over the past decade many advanced technologies have been patented. Nevertheless a need for additional research and continuous innovation is still warranted. Patent literature is often essential for promoting new directions in research as well as for elucidating possibilities for future technologies. Hence, the aim of this review article is to discuss several recently filed patents on non-invasive modes of drug delivery to the ocular tissues. This review will also focus on the role of colloidal/particulate systems in ocular drug delivery and formulation. Recent patents filed on prodrugs as an efficient ophthalmic drug delivery mechanism also have been discussed. As a whole, this article is intended to provide a valuable insight into current trends in the field of ocular drug delivery and highlights advances made in patent literature.
长期以来,对于致力于缓解影响眼前段和后段的各种眼部疾病的药物科学家而言,眼部给药一直是一项具有挑战性的任务。为了将治疗剂递送至靶组织,必须有效规避眼睛独特的解剖学屏障,同时又不引起任何患者不适或改变保护性生理机制。目前,新型非侵入性给药方法的开发以及对现有技术的改进正在应对这一挑战。在过去十年中,许多先进技术已获得专利。然而,仍有必要进行更多研究和持续创新。专利文献对于推动研究新方向以及阐明未来技术的可能性通常至关重要。因此,本文的目的是讨论最近提交的几项关于眼部组织非侵入性给药模式的专利。本综述还将关注胶体/颗粒系统在眼部给药和制剂中的作用。还讨论了最近提交的关于前药作为一种有效眼部给药机制的专利。总体而言,本文旨在深入了解眼部给药领域的当前趋势,并突出专利文献中取得的进展。